WASHINGTON DC — The federal government’s long-awaited shift on marijuana policy is no longer theoretical—it’s happening in real time.

In a major step forward, the Drug Enforcement Administration has formally scheduled a June 29 hearing that could determine whether marijuana as a whole—including recreational cannabis—will be reclassified from Schedule I to Schedule III under federal law.

At the same time, a separate and immediate decision is already reshaping the industry: FDA-approved and state-legal medical marijuana has effectively been moved to Schedule III, giving qualifying businesses access to long-denied tax and regulatory relief.

Together, the moves mark the most significant federal cannabis policy shift in decades—and set up a high-stakes battle over what comes next.

Medical Marijuana: Immediate Impact, Real Money

For medical marijuana operators, the impact is already tangible.

Under current law, cannabis businesses have been subject to IRS Section 280E, which prevents companies dealing in Schedule I substances from deducting ordinary business expenses. That has left many dispensaries paying effective tax rates as high as 60 to 80 percent.

With the move to Schedule III, that restriction is lifted only for medical marijuana.

Those dispensaries can now deduct standard expenses such as payroll, rent and marketing—potentially cutting their tax burden in half and restoring profitability across the industry.

The shift carries particular significance in Michigan, where the cannabis market is overwhelmingly driven by recreational sales. According to the Michigan Cannabis Regulatory Agency, medical marijuana sales in March totaled less than $500,000, compared with roughly $255 million in adult-use sales.

That imbalance means the federal government’s immediate move to ease restrictions on medical marijuana will benefit only a small slice of the state’s industry—at least for now—while the far larger recreational market waits on the outcome of the June hearing.

DEA Opens the Door to Federal Protections

The policy shift is not just symbolic—it’s operational.

The DEA is now beginning to accept applications from medical marijuana businesses seeking federal registration under the new Schedule III framework. A new registration portal allows qualifying operators to formally align with federal law for the first time.

Applicants will need to meet federal compliance standards, including security protocols, reporting requirements and disclosure rules.

That creates a new reality: while the policy offers relief, it also introduces stricter oversight.

For smaller operators, the transition could be challenging.

Banking Improves—But Isn’t Fixed

Rescheduling also begins to ease one of the industry’s biggest constraints: access to banking.

Because marijuana has been classified as a Schedule I drug, many financial institutions have avoided the industry altogether.

Moving to Schedule III reduces legal risk for banks, making it easier for cannabis businesses to access basic financial services such as checking accounts, payment processing and potentially credit.

However, full normalization is still out of reach without congressional action, such as passage of the SAFE Banking Act.

In other words: progress, but not a complete solution.

The Bigger Fight: Recreational Marijuana

While medical marijuana is already seeing federal relief, the broader question—what happens to recreational cannabis—remains unresolved.

That’s where the June 29 hearing comes in.

The proceeding, scheduled to run through mid-July, will allow federal officials to review evidence and expert testimony on whether marijuana as a whole should be moved to Schedule III under the Controlled Substances Act.

The hearing follows a recommendation from the Department of Health and Human Services that marijuana has accepted medical use and a lower abuse potential than Schedule I substances.

But the outcome is far from guaranteed.

Timeline: Fast for Washington, Still Months Away

Even under an expedited process ordered by the U.S. Department of Justice, a final decision will take time.

Based on prior federal drug rescheduling efforts, the process typically includes:

  • Administrative hearing
  • Review of evidence and testimony
  • Drafting of a final rule
  • Potential legal challenges

Best-case scenario: a final rule by late 2026.

More likely: November or December 2026.

And if lawsuits emerge—as many expect—the timeline could slip into 2027.

That aligns with what many industry insiders are already saying: recreational marijuana rescheduling is possible this year, but far from certain.

Winners, Losers, and What Comes Next

The shift to Schedule III is expected to trigger a wave of change across the cannabis industry.

Winners:

  • Medical marijuana operators gaining tax relief
  • Larger companies positioned to expand
  • Investors previously sidelined by federal risk

Potential losers:

  • Smaller dispensaries unable to meet new compliance requirements
  • Operators squeezed by increased competition and consolidation

Michigan’s cannabis market—already one of the most competitive in the country—could see significant disruption as capital flows in and margins tighten.

At the same time, the federal government is signaling a broader shift: from prohibition toward regulation.

Medical marijuana has effectively crossed the federal line into legitimacy.

Recreational cannabis is now racing to catch up.

The June hearing will determine whether that transition happens quickly—or becomes mired in the same legal and political battles that have defined cannabis policy for decades.